Szczepaniak Sloane Robert A, Gopalakrishnan Vancheswaran, Reddy Sangeetha M, Zhang Xue, Reuben Alexandre, Wargo Jennifer A
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer. 2017 Jun 1;123(S11):2130-2142. doi: 10.1002/cncr.30681.
Major advances have been made in melanoma treatment with the use of molecularly targeted therapies and immunotherapies, and numerous regimens are now approved by the US Food and Drug Administration for patients with stage IV disease. However, therapeutic resistance remains an issue to both classes of agents, and reliable biomarkers of therapeutic response and resistance are lacking. Mechanistic insights are being gained through preclinical studies and translational research, offering potential strategies to enhance responses and survival in treated patients. A comprehensive understanding of the immune effects of common mutations at play in melanoma is critical, as is an appreciation of the molecular mechanisms contributing to therapeutic resistance to immunotherapy. These mechanisms and the interplay between them are discussed herein. Cancer 2017;123:2130-42. © 2017 American Cancer Society.
在黑色素瘤治疗中，分子靶向疗法和免疫疗法取得了重大进展，目前美国食品药品监督管理局已批准多种方案用于治疗IV期疾病患者。然而，这两类药物都存在治疗耐药性问题，且缺乏可靠的治疗反应和耐药生物标志物。通过临床前研究和转化研究，我们对其作用机制有了更深入的了解，这为提高治疗患者的反应率和生存率提供了潜在策略。全面了解黑色素瘤中常见突变的免疫效应至关重要，同样重要的是要认识到导致免疫治疗耐药的分子机制。本文将讨论这些机制及其相互作用。《癌症》2017年；123:2130 - 42。© 2017美国癌症协会。
